Long-term follow-up from the NRG Oncology GY018 Phase 3 trial reinforced survival benefits from adding pembrolizumab to standard chemotherapy for advanced or recurrent endometrial cancer. The updated analysis followed earlier immature overall survival readouts that had suggested improvement with the immunotherapy combination. NRG Oncology reported that continued monitoring further supported the clinical signal for patients when pembrolizumab is incorporated alongside chemotherapy, aiming to solidify the role of checkpoint inhibition in a disease area where treatment selection remains highly stratified. The follow-up results address the key question of durability rather than short-term response metrics. Clinicians and payers are likely to focus on how the extended follow-up affects overall survival and treatment durability across subgroups, since those details often drive label strategy and future study designs. The GY018 findings also keep pressure on competing immunotherapy-led combination approaches in gynecologic oncology. For biotech teams, the update illustrates how Phase 3 outcomes can mature into regulatory momentum when subsequent monitoring confirms benefit beyond early cutoffs.